Cagrilintide vs Exenatide

Cagrilintide is an experimental long-acting amylin-like drug still in development, while Exenatide is an FDA-approved GLP-1 receptor agonist available as Byetta (short-acting) and Bydureon (long-acting). Exenatide is approved to treat type 2 diabetes, whereas Cagrilintide has no approved uses yet. Exenatide is made by Amylin Pharmaceuticals and is taken by injection, while Cagrilintide’s maker and delivery method have not been specified in the provided details.

AI summary of the sources below.